The identification of proinflammatory signal transduction pathways may suggest new therapeutic targets. In this study, we examine which signaling pathways are involved in tumor necrosis factor (TNF)-induced matrix metalloproteinase 9 (MMP9) secretion in human chorionic trophoblast (CT) cells. Purified CT cells were cultured in the presence of antibodies or chemical inhibitors that specifically block/inhibit distinct TNF receptors and kinase pathways. TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/ inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P , 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125). By Western blot analysis, we found that TNF rapidly and significantly increased phosphorylation of IKBKB, MAPK1/3, and MAPK8/9/10 and that the phosphorylation of these kinases by TNF was reduced significantly by TNFRSF1A neutralizing antibody, but not by TNFRSF1B neutralizing antibody. Moreover, we found that TNF increased TNF receptor-associated factor (TRAF) 1 and decreased TRAF2 protein expression through TNFRSF1A, but not TNFRSF1B. The CT cells that had increased TRAF1 and decreased TRAF2 after an initial TNF treatment demonstrated a dramatic deficiency in phosphorylation of the above protein kinases following a secondary TNF treatment. Localization of RELA subunit by immunocytochemistry was shifted to the nuclei after TNF treatment compared to cytosol in untreated controls. We also found cross-talk between the phosphoinositide 3-kinase pathway and ERK pathway. In summary, we have demonstrated that TNF stimulates proMMP9 production in CT cells through TNFRSF1A-TRAFs-IKBKB-NFKB and ERK signaling pathways, but not through TNFRSF1B and JNK/p38-AP-1 pathways.
INTRODUCTION
Preterm delivery caused by preterm premature rupture of membranes (pPROM) and preterm labor (PTL) is a major unresolved clinical problem and an important cause of perinatal morbidity and mortality. Both prevention and treatment of pPROM and PTL present a considerable challenge because of an incomplete understanding about the pathological and physiological mechanisms of pPROM and PTL. However, increasing evidence suggests that inflammation of the genital tract may play a major role in the pathogenesis of PTL [1, 2] . In turn, this suggests important roles for immunological effectors, such as cytokines, which are important in ovulation, implantation, placentation, and parturition [3] . Increased concentrations of tumor necrosis factor (TNF), interleukin (IL) 1, IL6, and IL8 have been found in the amniotic fluid of women with infection-associated PTL [4] [5] [6] [7] . Furthermore, the direct administration of TNF induces PTL and fetal death in animal models, whereas anti-TNF antibodies can reduce the incidence of preterm birth [8] . These results suggest that TNF may play a critical role in the pathogenesis of preterm delivery.
The role of matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in the decidua and fetal membranes have received increasing attention in terms of the pathological and physiological processes of tissue destruction leading to rupture of the membranes at term labor, pPROM, and PTL and in terms of the clinical prevention and treatment of pPROM and PTL. Abnormal degradation of the extracellular matrix by MMPs in the fetal membranes has been proposed as the central event in pPROM and PTL. Downregulation of MMP expression and production has been proposed as a potential therapeutic target to reduce extracellular matrix degradation and risk of pPROM and PTL. Several studies have shown that TNF can stimulate production of MMP1, MMP3, and MMP9 in cultured human fetal membranes, chorion trophoblast, and decidual cells in vitro [9] [10] [11] . More recently, the cell signaling pathways that generate the inflammatory and tissue destruction proteins have been recognized as therapeutic targets [12, 13] .
Considerable progress has been made in understanding the molecular mechanisms that mediate TNF-induced cellular responses in different cell types. TNF transduces its signals by binding to TNF receptor 1 (TNFRSF1A) and TNF receptor 2 (TNFRSF1B). After TNF binding, TNF receptors undergo a conformational change, allowing them to recruit adapter molecules that then initiate the activation of intracellular signaling pathways. The first adapter molecule recruited to TNFRSF1A is TNFRSF1A-associated death domain protein (TRADD). TNFRSF1A-bound TRADD then serves as an assembly platform for binding of TNF receptor-associated factors (TRAFs 1-6), receptor-interacting serine-threonine kinase (RIPK1), and the adapter molecule Fas (TNFRSF6) associated via death domain (FADD [14, 15] . Understanding the molecular mechanisms by which TNF governs MMP expression and production in local resident cells within maternal and fetal tissue is key for the development of therapeutics that may stop inflammatory tissue destruction in preterm deliveries associated with increased TNF. Although a previous study has demonstrated the involvement of the MAPK pathway in TNF-induced MMP9 expression in human first-trimester placental trophoblasts [16] , the underlying cell signaling pathways explaining TNF-induced MMP production in chorion trophoblasts from human term fetal membranes are still unknown. Therefore, we set out to characterize the signaling pathways that regulate TNF-induced MMP production and release in chorion trophoblast cells. 6-amino-4-(4-phenoxy-phenylethylamino)quinazoline]) were obtained from Calbiochem. Gelatin and antibiotics mix (1003) were obtained from Sigma; lysis buffer (103) and rabbit polyclonal phospho-MAPK8 (SAPK/JNK), MAPK8, and phospho-CHUK/IKBKB antibodies were from Cell Signaling. Mouse monoclonal TNFRSF1A, TNFRSF1B, TRAF1, TRAF2, phospho-MAPK1/3, and MAPK1/3 antibodies were from Santa Cruz Biotechnology; rabbit polyclonal RELA (p65) antibody was from eBioscience. Enhanced chemiluminescence Western blotting detection system and peroxidaseconjugated sheep anti-mouse immunoglobulin (Ig) G or peroxidase conjugated donkey anti-rabbit IgG were obtained from Amersham Biosciences. Highcapacity cDNA reverse transcription kit was from Applied Biosystems, and Immolase DNA polymerase kit was from Bioline. Vector ABC kit for immunocytochemistry was obtained from Vector Laboratories.
MATERIALS AND METHODS

Reagents
Human Fetal Membrane Collection and Chorion Trophoblast Cell Cultures
Placentas with attached fetal membranes were collected from normal term (.37 wk of gestation) pregnancies after elective cesarean delivery in the absence of labor (n ¼ 16). Patient consent was obtained before tissue collection. The present study was approved by the Review Board for Human Subject Research (IRB no. 04-0018-U) at Mount Sinai Hospital (Toronto, ON, Canada) and the University of Toronto in accordance with the Canadian Tri-Council Policy Statements on Human Ethics Reviews. Patients who had multifetal gestations, preterm rupture of membranes, chorioamnionitis, chromosomal abnormalities, and/or preeclampsia were excluded. None of the patients had received prostaglandins, corticosteroids, or oxytocin. The indications for elective cesarean section included breech presentation, previous cesarean delivery, and cephalopelvic disproportion. None of the women had experienced premature uterine activity during their pregnancy. Chorionic trophoblast cells were prepared using a modification of the method of Kliman, as described previously [17] . Briefly, the amnion and decidua were separated from the chorionic membrane. The chorion tissues were then digested three times for 60 min each time with DMEM containing 0.2% collagenase (Sigma) without DNase I. The chorionic cells were loaded onto a 5-75% Percoll (Sigma) gradient at step increments of 5% Percoll and then centrifuged at 378C at 2500 3 g for 20 min to separate different cell types. Cytotrophoblasts between the density markers of 1.049 and 1.062 g/ml were collected.
Cells were plated in 24-well plates (0.5 3 10 6 cells/well for zymography or 5 3 10 6 cells in 60-mm diameter dishes for Western blotting) and cultured in DMEM/F-12 supplemented with 10% fetal calf serum and antibiotics (1000 U/ ml of penicillin, 0.1 mg/ml of streptomycin, and 0.23 lg/ml of amphotericin) at 378C under 5% CO 2 /95% O 2 for 72 h. The serum-free DMEM/F-12 was then used to replace the culture medium. After 8-12 h of starvation and/or preincubation, further treatments were added, and the cells were incubated for different time periods as described. Vehicle-treated wells (controls) were present in each experiment. After incubation, the medium was harvested, and cells were used for protein or total RNA extraction. All samples were stored at À808C until further assay.
Zymography for MMP9
To detect proteolytic activity in conditioned media, approximately 10-20 ll of harvested culture medium (10 lg of cell protein) were electrophoresed under nonreducing conditions in a 10% acrylamide gel containing 1 mg/ml of gelatin (Sigma-Aldrich Corp.) according to the method described by Fisher and Werb [18] . After electrophoresis, the gels were washed at room temperature for 1 h in 2.5% Triton X-100 and 50 mM Tris-HCl (pH 7.5), then incubated at 378C overnight in buffer containing 150 mM NaCl, 5 mM CaCl 2 , and 50 mM TrisHCl (pH 7.6). Thereafter, gels were stained with 0.1% (wt/vol) Coomassie Brilliant Blue R-250 in 30% (vol/vol) isopropyl alcohol/10% glacial acetic acid for 60 min and destained in 10% (vol/vol) methanol/5% (vol/vol) glacial acetic acid. Quantification of the bands corresponding to MMP9 (92-kDa gelatinase) and MMP2 (72-kDa gelatinase) were performed by densitometry using Scion Image software (Scion Corp.).
Western Blot Analysis
Total protein (5-20 lg) per lane was incubated in SDS-PAGE sample buffer, subjected to SDS-PAGE analysis with 10% acrylamide gel, and then electrotransferred onto a nitrocellulose membrane. The membrane was blocked in 5% skim milk powder in 0.1% Tris-buffered saline/Tween 20 overnight. The membrane was then incubated with one of the antibodies described above, followed by incubation with the appropriate secondary antibody of either peroxidase-conjugated sheep anti-mouse IgG or peroxidase-conjugated donkey anti-rabbit IgG (Amersham Biosciences). Immunoreactive proteins were visualized using the enhanced chemiluminescence Western blotting detection system.
RNA Isolation, RT-PCR, and Real-Time Quantitative PCR Analysis
Total RNA was isolated by using TRIzol reagent according to the manufacturer's instructions, and the RNA was reverse transcribed using superscript reverse transcriptase. The forward and reverse primers used were, respectively, [21] . Amplification was performed using Immolase DNA polymerase kit (plus 0.0032% [vol/vol] SYBR green [Molecular Probes, Invitrogen] for real-time PCR) on a PTC-220 (Peltier Thermal Cycler; MJ Research, Inc.) for RT-PCR and a Rotor-Gene SG3000 system for real-time PCR. PCR cycles consisted of an initial denaturation step at 958C for 10 min, followed by 40 cycles of denaturation at 958C for 30 sec, annealing for 30 sec at 558C (TNFRSF1A, TNFRSF1B, TRAF1, TRAF2, and RIPK1) or 608C (TNF, TRADD, and FADD), and elongation for 60 sec at 728C, with a final elongation step for 10 min at 728C (for RT-PCR only). The RT-PCR products were separated by electrophoresis in 1.5% agarose gel with ethidium bromide. Correct size was verified by comparison with a 100-bp ladder. For real-time PCR, amplification of ACTB was measured in each sample and used as a housekeeping gene for normalization. Data were analyzed using the comparative difference in cycle number (DCT) method. Specificity of the amplified PCR product was verified by melting-point analysis.
Nuclear Translocation of RELA (Immunocytochemistry)
Chorionic trophoblast cells, grown on a chamber slide, were washed with 0.1 M PBS (pH 7.4) and fixed in acetone/ethanol mix (1:1) for 10 min at À208C. Staining was performed according to the protocol described with the Vector ABC kit. After several washes with PBS, the cells were permeabilized with 0.1% Triton X-100 in PBS for 15 min. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in absolute methanol for 15 min at 482 room temperature. Cells were incubated overnight at 48C with a rabbit anti-p65 (human) antibody diluted 1:50 in PBS containing 1% bovine serum albumin, then washed and incubated with biotinylated horse anti-rabbit IgG at room temperature for 1 h, followed by incubation with avidin-biotin-peroxidase complex for 1 h at room temperature and incubation with a combination of 3,3 0 -diaminobenzidine tetrahydrochloride for 1-3 min at room temperature. Finally, the slides were mounted. As a negative staining control, the tissue section was treated in an identical manner with the omission of primary antibody.
Analysis of Data
Statistical analysis was carried out by ANOVA and Tukey test. Results are expressed as the mean 6 SEM for the number of different experiments. Statistical significance was set at P , 0.05. Calculations were performed using SigmaStat (Jandel Scientific Software). Figure 1 illustrates the effect of TNF on the secretion of proMMP9 and proMMP2 from cultured human fetal membrane CT cells. The active forms of MMP9 and MMP2 were undetectable by zymographic analysis under our experimental condition. CT cells treated with TNF (0.1-20 ng/ml) produced a significant dose-dependent increase in proMMP9 output at 18 h compared with untreated control. The level of proMMP2 was not changed significantly in the medium of CT cells by TNF.
RESULTS
Effect of TNF on Secretion of MMP9 CT Cells
Expression of TNF, TNF Receptors, and Its Relatives and Effects of TNF and TNF Receptors on Expression of TNF Receptors and Its Relatives
The expression of mRNA for TNF, TNF receptors, and its relatives in CT cells was investigated by RT-PCR and real-time quantitative PCR analysis. The results show that TNF, TNFRSF1A, TNFRSF1B, TRAF1, TRAF2, TRADD, FADD, and RIPK1 mRNA were all detected in CT cells (Fig. 2A) . We also found that mRNA expression of TNFRSF1A was higher than that of TNFRSF1B; TNFRSF1B mRNA expression was very low under our experimental conditions. The level of TRAF2 mRNA was higher than that of TRAF1 (Fig. 2A) . A similar pattern of results was obtained by Western blot analysis (Fig. 2B) . Expression of TNFRSF1A protein was greater than TNFRSF1B protein, which was undetectable under our experimental conditions. TRAF2 protein expression was consistently higher than that of TRAF1 (Fig. 2B) . Moreover, we found that TRAF1 protein level was increased by TNF in a time-dependent manner after 4 h of treatment and that TRAF2 protein level was reduced by TNF. No effect was found on TNFRSF1A protein (Fig. 2C) . We found that TNF-induced TRAF1 protein expression was blocked by anti-TNFRSF1A neutralizing antibody, but not by anti-TNFRSF1B neutralizing antibody. TNF-induced reduction of TRAF2 protein expression was not affected by either of the neutralizing antibodies. Additionally, TNF-induced TRAF1 protein expression was blocked by U0126 and NFKBAI, but not by SP600125 (Fig.  2D) .
Role of TNF Receptors in TNF-Induced proMMP9 Secretion
TNF can bind and signal through TNFRSF1A and TNFRSF1B. Our expression experiments indicated that TNFRSF1A mRNA, TNFRSF1B mRNA, and TNFRSF1A protein were detectable in CT cells. Therefore, we used receptor-specific neutralizing antibodies to determine the specific role of each receptor subtype with respect to increasing proMMP9 secretion using zymography. The secretion of proMMP9 was reduced significantly in the cells treated with neutralizing anti-TNFRSF1A antibody and anti-TNF antibody (P , 0.01). However, neutralizing anti-TNFRSF1B antibody had no effect on proMMP9 secretion (Fig. 3) . The output of proMMP2 was not affected by any of these treatments.
Inhibition of TNF-Induced proMMP9 Secretion by MAPK and NFKBAI
To examine whether MAPK1/3, MAPK8/9/10 (JNK), MAPK14, and NFKB activation was involved in the signal transduction pathway leading to proMMP9 expression caused by TNF, different MAPK inhibitors and NFKBAI were added 3 h before TNF treatment of CT cells. Inhibitors of MAPK1/3 (U0126) and NFKB (NFKBAI), respectively, significantly decreased the TNF-induced proMMP9 secretion (P , 0.01). Inhibition of MAPK8/9/10 (JNK) (SP600125) slightly decreased the TNF-induced proMMP9 secretion (P ¼ 0.063). The MAPK14 inhibitor (SB203580) had no effect on the TNFinduced proMMP9 secretion (Fig. 4) .
Role of TNF, TNF Receptors, and TRAFs in Phosphorylation of MAPK and NFKB
It is well-known that the activation of MAPK1/3, NFKB, and MAPK8/9/10 requires phosphorylation. We therefore examined MAPK1/3, CHUK/IKBKB, and MAPK8/9/10 phosphorylation by Western blotting using phospho-specific antibodies for phospho-MAPK1/3, phospho-CHUK/IKBKB, and phospho-MAPK8/9/10. CT cells were treated with TNF for different time periods (5, 15, 30, and 60 min). We found that IKBKB phosphorylation was undetectable in untreated cells, but after TNF treatment, it had increased at 5 min, peaked at 15 min, and then decreased after 30 min. Conversely, CHUK phosphorylation was detectable in untreated cells and was not changed by TNF treatment. IKBKB protein expression was also unaffected by TNF. Phosphorylated forms of MAPK1/3 and MAPK8/9/10 were detectable in untreated cells, and these increased rapidly with TNF to peak within 15 min and then decreased after 30 min. MAPK1/3 and MAPK8/9/10 protein expression were not affected by TNF (Fig. 5A, first 5 lanes) .
Because we had demonstrated that TNFRSF1A was involved in TNF-induced MMP9 secretion (see Fig. 3 ), we next determined the contribution of TNFRSF1A and TNFRSF1B in the phosphorylation of MAPK and CHUK/ IKBKB in CT cells. As shown in Figure 5B , phosphorylation of IKBKB, MAPK1/3, and MAPK8/9/10 was mediated principally by TNFRSF1A. Similar to the regulation of 
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MMP9 secretion by TNF, TNFRSF1B was not involved in TNF-induced phosphorylation of IKBKB, MAPK1/3, and MAPK8/9/10.
As shown in Figure 2 , B and C, TRAF2 protein level was higher than TRAF1 in untreated cells. Conversely, the TRAF1 level was higher than TRAF2 after TNF treatment for 4 h. To test the effect of these changes on activation of MAPK and NFKB by secondary TNF treatment, we stimulated CT cells with TNF treatment for 18 h (to induce a reduction of TRAF2 and an increase of TRAF1) and then restimulated them at a later time point with secondary TNF treatment. We found that CT cells receiving a second TNF treatment after the initial TNF treatment exhibited a dramatic reduction in phosphorylation of IKBKB, MAPK1/3, and MAPK8/9/10 ( Fig. 5A, last 5 lanes) .
Analysis of the RELA nuclear translocation was conducted using immunocytochemistry. CT cells cultured on sterile chamber slide were stimulated with TNF for 30 min. As shown in Figure 5C , staining of RELA was localized in the cytoplasm in untreated cells. In TNF-treated cells, it was present within the nucleus.
Effect of PI3K on TNF-Induced proMMP9 Secretion and Cross-Talk with ERK Pathway
Previous studies have shown cross-talk between protein kinase (PRKC and AKT) and TNF signaling complexes [14] . To test whether some protein kinases are involved in TNFinduced proMMP9 secretion in CT cells, we used protein kinase inhibitors of PRKC (calphostin C), PRKA (KT5720), PLC (U73122), and PI3K (wortmanin). We found that wortmanin modestly inhibited TNF-induced proMMP9 secretion (P , 0.05) but that calphostin C, KT5720, and U73122 had no effects (Fig. 6A) . We also found that wortmannin dramatically inhibited phosphorylation of MAPK1/3 by TNF (Fig. 6B) . 
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DISCUSSION
TNF has a pivotal role in the process of inflammation. Blocking TNF action has been shown to reduce delivery effectively in an animal model of infection-driven preterm birth [8] . Indeed, blockade of TNF, TNF receptors, and the subsequent transduction pathway can be used not only as a probe to understand the molecular basis of TNF-induced MMP expression but also as a target for development of a therapeutic agent. In the present study, we demonstrated that human chorionic trophoblast cells express TNFRSF1A, TNFRSF1B and their relatives, TRADD, TRAF1, TRAF2, RIPK1, and FADD at the level of mRNA, but TNFRSF1B mRNA is at a very low level. TNFRSF1A protein was detectable in human chorionic trophoblast cells, but TNFRSF1B was undetectable under our experimental conditions. The increase in TRAF1 and phosphorylation of MAPK1/3, MAPK8/9/10, and IKBKB after TNF treatment were blocked completely by neutralizing anti-TNFRSF1A antibody, but not by neutralizing anti-TNFRSF1B antibody. Taken together, these findings suggest that TNFRSF1A, rather than TNFRSF1B, is the important receptor involved in TNF-initiated signaling cascades and subsequent proMMP9 secretion in human chorionic trophoblast cells. We speculate that blocking TNFRSF1A activity may be helpful in the clinical treatment of infection/inflammation-related PTL and preterm pPROM.
After formation of TNF-TNF receptor-TRADD platform to initiate the intracellular signaling pathway, further recruitment of other TNF receptor-related adaptor molecules (TRAFs 1-6 and/or RIPK1) is essential for subsequent signaling transduc- tion. Among these adaptors, TRAF1 and TRAF2, have been intensively studied and shown to be important in the initiation of subsequent signaling cascades by TNF. TRAF2 has been suggested to play a crucial role in MAPK (ERK, p38 MAPK, and JNK), NFKB, and AP-1 activation [14, 22] . However, TRAF1 has little or no effect on ligand-independent receptor signaling activation, but it appears to both negatively or positively regulate the activation induced by other mediators [15] . In the present study, we demonstrated that human chorionic trophoblast cells expressed TRAF1 and TRAF2 at mRNA and protein levels. TRAF2 was expressed more highly than TRAF1 at both mRNA and protein levels in non-TNFtreated cells. However, after TNF treatment, TRAF2 protein level was reduced, but TRAF1 protein level was increased, resulting in TRAF1 expression being higher than that of TRAF2. The increase of TRAF1 by TNF was blocked by a neutralizing anti-TNFRSF1A antibody, by U0126, and by NFKBAI, consistent with previous results that TRAF1 is inducible by ligands of the TNF family and regulated through the NFKB pathway [15] . However, the reduction of TRAF2 by TNF was blocked by a neutralizing anti-TNFRSF1A antibody only, and not by U0126 or NFKBAI. It has been reported that TRAF2 is degraded after ligand-induced association with the TNFR superfamily [23] , suggesting that in CT cells, TNFRSF1A mediates not only TNF-induced MMP9 secretion but also TRAF2 degradation. Additionally, it has been proposed that TRAF degradation is a method for downregulating a receptor signal cascade [23] . Further results of the present study indicate that reduced TRAF2 and increased TRAF1 correlated with a concomitant dramatic deficiency in phosphorylation of IKBKB, MAPK1/3, and MAPK8/9/10 in CT cells. These results suggest that TRAF2 exerts a positive effect on MAPK and NFKB activation. They also imply that TRAF1 exerts a negative effect and that TRAF2 degradation and TRAF1 upregulation induced by an initial burst of TNF can limit continued or subsequent TNF-mediated activation. Whether TRAF1 actually does exert a negative effect as well as the significance of self-limitation by TNF on signaling activation in CT cells require future investigation.
MAPK signaling pathways leading to increased expression of MMP9 have already been studied in different TNFstimulated cells [23] [24] [25] [26] . It has been shown that TNF induces MMP9 secretion from eosinophils via the MAPK14, but not the MAPK1/3, pathway [25] . In contrast, TNF-induced MMP9 expression in keratinocytes involved the MAPK1/3 pathway, NFKB, and AP-1 activation, but not MAPK14 and MAPK8/9/ 10 activation [24, 25] . These reports suggest that the MAPK pathway involved in TNF-induced MMP9 secretion and expression is dependent on cell type. In CT cells, the present results demonstrate that TNF-induced proMMP9 secretion was completely inhibited by treatment with NFKBAI, and that the phosphorylation of IKBKB induced by TNF was detectable, but not changed on phosphorylation of CHUK. NFKB is activated after NFKBI (I KB) has been phosphorylated and subsequently degraded by the proteosome, enabling the liberated NFKB dimers to enter the nucleus and initiate transcription of genes with KB sites. Phosphorylation of NFKBI is mediated by a high-molecular-weight IKBK complex that consists of the regulatory subunit I kappa beta kinase gamma and two catalytic subunits, CHUK and IKBKB. Both catalytic IKBK subunits are capable of inducing NFKBI phosphorylation. In the present study, phosphorylation of IKBKB was inducible by TNF, suggesting that IKBKB, but not CHUK, is required for activation of NFKB in CT cells. Previous studies have shown that IKBKB is not only involved in the regulation of NFKBI phosphorylation but is also the predominant kinase for phosphorylation of RELA subunit in its transactivation domain [27] . Our results demonstrated that RELA subunit translocated to the nucleus in response to TNF treatment. It is possible that TNF-induced phosphorylation of IKBKB results not only in the phosphorylation of NFKBI but also in a concomitant phosphorylation of RELA subunit in CT cells. Thus, the IKBKB-NFKBI-RELA pathway is one of the TNF-TNFRSF1A-TRAF2 complex subsequent pathways in CT cells. Recently, specific pharmacological inhibitors of IKBKB have been shown to be highly effective in preventing hepatic ischemia/reperfusion injury [28] . Thus, IKBKB deletion may also be a potential target for the treatment of infection/inflammation-related PTL and pPROM. On the other hand, complete inhibition of TNF-induced MMP9 by U0126 and increased phosphorylation of MAPK1/3 by TNF suggests that activation of the ERK pathway is another subsequent intracellular signaling pathway in TNF-induced proMMP9 secretion in CT cells.
TNF-induced proMMP9 secretion and phosphorylation of MAPK1/3 by TNF were blocked by wortmannin, suggesting cross-talk between the ERK pathway and the AKT pathway. The downstream events of MAPK1/3-mediated transduction in TNF-induced proMMP9 secretion in CT cells remain to be investigated. Although stronger phosphorylation of MAPK8/9/ 10 by TNF was induced in the present study, TNF-induced proMMP9 secretion was inhibited with treatment with SP600125, suggesting that in CT cells, the JNK-AP-1 pathway is necessary, but not sufficient, for a complete transactivation of MMP9. Also, we found that the MAPK14, PRKC, PRKA, and PLC pathways were not involved in TNF-induced MMP9 secretion and TNF-induced MMP1 and MMP3 secretion (data not shown) in CT cells under our experimental conditions. More recently, Oner et al. [11] demonstrated that the MAPK14 pathway was involved in TNF-induced MMP1 and MMP3 in human decidual cells. This suggests that the different signaling pathways may play different roles at the fetus-maternal interface.
In conclusion, we have shown that in human chorionic trophoblast cells, activation of the IKBKB-NFKB and MAPK1/3 pathways plays the dominant role in MMP9 secretion in response to TNF instead of the JNK/p38 MAPK pathway. Furthermore, we conclude that TNFRSF1A-TRAF2-IKBKB-NFKB and TNFRSF1A-TRAF2-MAPK1/3 signaling pathways are the major determinants of TNF-induced MMP9 secretion in human chorionic trophoblast cells. These results may support further evaluation of the blockade of TNF, TNFRSF1A, or inhibition of IKBKB, NFKB, and MAPK1/3 activation as potential therapeutic targets for PTL and pPROM.
